A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

NCT ID: NCT06304974

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 497 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-19
• Study Completion Date: 2026-05-31

Brief Summary

This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.

Conditions

Esophageal Squamous Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental Group

Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion

Control group

Participants receive Irinotecan or paclitaxel or docetaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

Irinotecan

Intervention Type: DRUG

Administration by intravenous infusion

paclitaxel

Intervention Type: DRUG

Administration by intravenous infusion

docetaxel

Intervention Type: DRUG

Administration by intravenous infusion

Interventions

BL-B01D1

Administration by intravenous infusion

Intervention Type: DRUG

Irinotecan

Administration by intravenous infusion

Intervention Type: DRUG

paclitaxel

Administration by intravenous infusion

Intervention Type: DRUG

docetaxel

Administration by intravenous infusion

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign the informed consent and follow the requirements of the protocol;

2. Age ≥18 years old;

3. Expected survival time ≥3 months;

4. Patients with recurrent or metastatic esophageal squamous cell carcinoma confirmed by histology or cytology;

5. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;

6. Must have at least one measurable lesion according to RECIST v1.1 definition;

7. ECOG 0 or 1;

8. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

10. No blood transfusion and no use of any cell growth factor drugs were allowed within 14 days before randomization, and the level of organ function had to be adequate;

11. Urine protein ≤2+ or < 1000mg/24h;

12. A serum pregnancy test must be performed within 7 days before the start of treatment for premenopausal women who are likely to have children, and the result must be negative and must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Chemotherapy, targeted therapy, biological therapy, etc., had been used within 4 weeks or 5 half-lives before randomization, and palliative radiotherapy and modern traditional Chinese medicine preparations approved by NMPA had been used within 2 weeks;

2. Patients with recurrent esophageal squamous cell carcinoma suitable for radical local treatment should be excluded;

3. Frontline received ADCs with topoisomerase I inhibitors as toxins;

4. History of severe heart disease and cerebrovascular disease;

5. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

6. diagnosed with active malignancy within 3 years before randomization;

7. Hypertension poorly controlled by two antihypertensive drugs;

8. patients with poor glycemic control;

9. present with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition; A previous history of interstitial lung disease (ILD) or a suspicion of such disease on imaging during screening;

10. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;

11. patients with active central nervous system metastases;

12. Severe infections within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;

13. patients with massive or symptomatic effusions or poorly controlled effusions;

14. Imaging examination showed that the tumor had invaded or wrapped around the large blood vessels in the abdomen, chest, neck, and pharynx;

15. serious unhealed wounds, ulcers, or fractures, or clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

16. patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;

17. patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;

18. had a history of autologous or allogeneic stem cell transplantation;

19. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;

20. a history of severe neurological or psychiatric illness;

21. received other unmarketed investigational drugs or treatments within 4 weeks before randomization;

22. subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;

23. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lin Shen, PHD

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

BL-B01D1-305

Identifier Type: -

Identifier Source: org_study_id